Dr. Jurcic on the Next Steps for Radioimmunotherapy

Joseph Jurcic, MD
Published: Monday, Jun 30, 2014

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses the next steps for research into radioimmunotherapy.

Radioimmunotherapy holds promise in multiple applications, Jurcic says. Preclinically, this therapy is being applied as conditioning for stem cell transplant. Encouraging results have been seen with beta-emitters.

Radioimmunotherapy may also be beneficial when using alpha particles to reduce toxicity yet gain an anti-tumor effect. In general, increasing the delivery of isotope to tumor cells but avoid toxicity has shown promise in preclinical studies.

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses the next steps for research into radioimmunotherapy.

Radioimmunotherapy holds promise in multiple applications, Jurcic says. Preclinically, this therapy is being applied as conditioning for stem cell transplant. Encouraging results have been seen with beta-emitters.

Radioimmunotherapy may also be beneficial when using alpha particles to reduce toxicity yet gain an anti-tumor effect. In general, increasing the delivery of isotope to tumor cells but avoid toxicity has shown promise in preclinical studies.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x